Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 11/20 | 0.39 |
| ▸ | RORC | P51449 | 4/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 3/20 | 0.37 |
| ▸ | RXRB | P28702 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | RORA | P35398 | 1/20 | 0.35 |
| ▸ | RORB | Q92753 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3343012 | 0.91 | GPBAR1 (0.38) | GPBAR1RORCFFAR4RXRARXRB | |
| SCHEMBL3342453 | 0.89 | GPBAR1 (0.43) | GPBAR1RORCFFAR4RXRARXRB | |
| SCHEMBL21803841 | 0.87 | FFAR4 (0.38) | GPBAR1RORCFFAR4FFAR1 | |
| SCHEMBL3341033 | 0.85 | GPBAR1 (0.37) | GPBAR1RORCFFAR4RXRARXRB | |
| SCHEMBL3340635 | 0.85 | RORC (0.37) | GPBAR1RORCRXRARXRBRXRG | |
| SCHEMBL3338239 | 0.84 | RORC (0.39) | GPBAR1RORCRXRARXRBRXRG | |
| SCHEMBL3337420 | 0.83 | GPBAR1 (0.42) | GPBAR1RORCFFAR4FFAR1 | |
| SCHEMBL3339726 | 0.83 | RORC (0.41) | GPBAR1RORCRXRARXRBRORA | |
| SCHEMBL3340821 | 0.83 | GPBAR1 (0.40) | GPBAR1RORCRORARORB | |
| SCHEMBL3338856 | 0.82 | GPBAR1 (0.38) | GPBAR1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422310-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2016-08-23 | — | — | US | claimed |
| US-20150183800-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2015-07-02 | — | — | US | claimed |
| EP-2155194-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2015-01-21 | — | — | EP | claimed |
| US-8084614-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | claimed |
| US-20100152207-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2010-06-17 | — | — | US | claimed |
| EP-2155194-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2010-02-24 | — | — | EP | claimed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | claimed |
| WO-2008124610-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | WO | claimed |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION | 2008-02-14 | — | — | US | claimed |
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-7696229-B2 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3A, HTR3B | GPBAR1 254/4885RORC 2517/4885FFAR4 249/4885 |
| US-20150183800-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | GPBAR1 76/4885RORC 850/4885FFAR4 235/4885 |
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3B, HTR1B | GPBAR1 214/4885RORC 3960/4885FFAR4 343/4885 |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | HTR6, HTR3B, HTR1B | GPBAR1 214/4885RORC 3960/4885FFAR4 343/4885 |
| US-20100152207-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | GPBAR1 76/4885RORC 857/4885FFAR4 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.